NCT07595718 AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases
| NCT ID | NCT07595718 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jae Yong Jeon, MD |
| Condition | Diabetes Mellitus Type 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-04-02 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-04-02 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop and validate an artificial intelligence (AI)-based predictive model to estimate the risk of incident onset of five major diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis, in adults aged 30 to 60 years. For each participant, an index date will be defined as the date of a prior health screening or another protocol-defined baseline clinical date. Incident disease status for each target disease or condition will be ascertained by retrospective review of electronic medical records for up to 10 years after the index date. The study integrates retrospective clinical, health screening, laboratory, imaging, and electronic medical record data with prospectively collected biospecimen, proteomic, genomic, questionnaire, lifestyle, and digital health data. Prospective study procedures will be completed over approximately 1 week, with up to 2 additional weeks if needed. By combining multimodal data, this study seeks to improve disease risk prediction and to identify clinical and biological factors associated with disease onset, ultimately supporting personalized risk stratification and preventive healthcare strategies.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 30 to 60 years. 2. Disease group: Participants with a confirmed diagnosis of at least one of the following conditions: type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain. 3. Healthy control group: Participants with no prior diagnosis of type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain. 4. No history or current diagnosis of major medical conditions that may affect study outcomes, including but not limited to chronic kidney disease or liver cirrhosis. 5. Ability to understand the study procedures and provision of written informed consent prior to participation. Exclusion Criteria: 1. Participants with incomplete or insufficient clinical or health screening data. 2. Participants considered inappropriate for study participation by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07595718 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 60 Years, studying Diabetes Mellitus Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07595718 currently recruiting?
Yes, NCT07595718 is actively recruiting participants. Contact the research team at jyjeon71@gmail.com for enrollment information.
Where is the NCT07595718 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07595718 clinical trial?
NCT07595718 is sponsored by Jae Yong Jeon, MD. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.